PROSTATE ADENOCARCINOMA

This study tests a combination of three treatments for prostate cancer that has spread to a few spots in the body. The treatments are a radioactive drug (radium-223), hormone therapy to lower testosterone, and precise radiation to tumors. The goal is to see if this triple approac…

This study tests whether a structured exercise program can slow or stop the progression of localized prostate cancer in men who are not yet receiving active treatment (active surveillance). Researchers will compare molecular and imaging markers of tumor aggressiveness between men…

This study tests whether a combination of two drugs (cabozantinib and atezolizumab) works better than standard hormone therapy for men with advanced prostate cancer that has stopped responding to initial hormone treatment. About 575 men with metastatic castration-resistant prosta…

This study tests whether using MRI scans to guide higher doses of radiation to the exact spot where prostate cancer has returned after surgery can better lower PSA levels. It involves 37 men whose PSA rose after prostate removal. The goal is to see if this targeted approach impro…

This study tests whether adding the drug relugolix to standard radiation therapy can delay cancer growth in men with prostate cancer that has spread to a few other body spots. Relugolix lowers testosterone, which some cancer cells need to grow. About 194 men will receive either r…

This study tests a type of radiation therapy called high-dose-rate brachytherapy for men with prostate cancer that hasn't spread. Doctors place tiny radioactive sources directly into the prostate to deliver a strong dose of radiation to the tumor while sparing nearby healthy tiss…

This study tests whether a daily dose of green tea catechins (a concentrated form of green tea) can prevent low- to intermediate-risk prostate cancer from getting worse in men who are already monitoring their cancer without immediate treatment. Over 24 months, 115 men will receiv…

This study tests two types of radiation therapy—proton beam and IMRT—given in shorter courses for men whose prostate cancer has come back and spread only to pelvic or abdominal lymph nodes. The goal is to see if the shorter treatment is safer and causes fewer severe side effects.…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy and hormone therapy can better control advanced prostate cancer that has spread. It includes 60 men with a specific genetic feature or inflamed tumors. The goal is to see if this combination…

This study tests whether a white button mushroom supplement can lower PSA levels in men with prostate cancer that has returned after treatment or is low-risk and being watched. About 133 men will take the supplement or be monitored as usual. The goal is to see if the mushroom aff…

This study tests whether combining surgery and radiation can help men whose prostate cancer has returned or spread to a few spots. About 20 participants will receive targeted radiation and/or surgical removal of those spots. The main goal is to see if this approach can significan…

This phase 2 trial tests a combination of abiraterone, prednisone, and apalutamide in 60 men with hormone-naive prostate cancer that has spread. The goal is to see how long patients can stay on treatment and how well it controls the cancer. Participants must have high-risk featur…

This early-stage trial tests a two-step treatment for men whose prostate cancer has returned after prostate removal surgery. First, doctors use a special scan to find exactly where the cancer is, then deliver targeted radiation. After that, patients receive a radioactive drug tha…

This study tests whether men with high-risk prostate cancer can receive treatment tailored to their genetic risk score. Those with a low genetic risk may get a shorter course of hormone therapy (12 months instead of 24) plus radiation, while those with a high genetic risk get an …

This study tests two drugs, golimumab and apalutamide, in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The goal is to see if blocking inflammation and male hormones together can shrink tumors or slow the cancer. Eight men partic…

This study tests whether using a genetic test (Decipher score) to guide prostate cancer treatment can improve outcomes. About 2,050 men with unfavorable intermediate-risk prostate cancer will be assigned to either more intense treatment (adding darolutamide to hormone therapy and…

This early-phase study tests whether placing bicalutamide implants directly into the prostate can replace standard hormone therapy (ADT) in men with localized prostate cancer who also receive radiation. About 20 participants with intermediate- or high-risk prostate cancer will re…

This study tests whether giving a combination of drugs (enteric-coated aspirin, rintatolimod, and possibly interferon-alpha 2b) before prostate cancer surgery can help the immune system fight the tumor more effectively. About 12 men with early-stage prostate cancer who are schedu…

This study tests whether taking apalutamide for 6 months before prostate removal surgery can reduce signs of aggressive cancer that often lead to radiation therapy afterward. It involves 45 men with intermediate-risk prostate cancer. The goal is to see if this approach can make s…

This study tests a treatment plan for men with high-risk prostate cancer that combines hormone therapy, external beam radiation, and a precise internal radiation implant guided by MRI. The goal is to see if this approach causes fewer side effects than standard treatments while st…

This study tests whether adding abiraterone and prednisone to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has come back after surgery or radiation. About 310 participants will receive either hormone therapy alone or hormone thera…

This study tests whether a very low dose of apalutamide, a drug that blocks testosterone, can lower PSA levels in men with early-stage prostate cancer who are about to have their prostate removed. About 34 men will take the drug for 3-4 weeks before surgery. If PSA drops enough, …

This early-phase study tests whether giving higher doses of radiation to the prostate in fewer sessions is safe for men with intermediate- to high-risk prostate cancer. The treatment also targets nearby lymph nodes. The main goal is to find a schedule that limits severe side effe…

This study tested whether adding enzalutamide to standard hormone therapy and chemotherapy could better control metastatic prostate cancer. Forty men with hormone-sensitive prostate cancer that had spread took part. The goal was to see if the triple combination was safe and more …

This study tests whether adding furosemide (a diuretic or "water pill") to a special PET/CT scan can reduce bladder radioactivity and improve detection of recurrent prostate cancer in 20 men whose PSA levels rose after prostate removal. Participants receive two scans—one with and…

This study tests a new 3D MRI technique to see if it can find prostate cancer better than standard MRI, without needing a special coil inside the body. About 33 men with untreated, intermediate- or high-risk prostate cancer who plan to have surgery will take part. The goal is to …

This study tests a new software that combines MRI images with real-time ultrasound to help doctors more accurately target and biopsy suspicious prostate lesions. The goal is to improve early detection of aggressive prostate cancer and guide better treatment decisions. The study i…

This study tests whether a special MRI contrast called hyperpolarized 13-C pyruvate can help doctors see prostate tumors more clearly than standard MRI. About 130 men with prostate cancer will receive this contrast during an MRI scan. The goal is to improve detection of high-risk…

This study tests a special PET scan called 68Ga-PSMA-11 to see if it can find prostate cancer more clearly than standard scans. About 141 men with prostate cancer that has come back or spread will get this scan. The goal is to see if the scan changes how doctors plan treatment, s…

This study compares two types of image-guided radiation therapy for prostate cancer: one using CT scans and the other using MRI. The goal is to see if MRI guidance reduces short-term side effects like urinary or bowel problems. About 179 men with localized prostate cancer will re…

This study collects tissue, blood, and urine samples from 92 men with prostate cancer that has spread. Researchers look for gene changes that might explain how well the cancer responds to standard hormone therapy. The goal is to find biomarkers, not to test a new treatment.

This early-phase study looks at whether a short course of hormone therapy can make prostate cancer cells show up brighter on PSMA PET scans. About 9 men with recurrent prostate cancer will take standard hormone pills for 4 weeks and get a scan before and after. The goal is to see…

This study looks at whether men with intermediate-risk prostate cancer can follow a Mediterranean diet for several weeks before their prostate removal surgery. The main goal is to see if this type of diet study is practical and well-tolerated. Researchers hope to learn how diet m…

This study looks at whether a DNA-based test can help predict which prostate cancer patients are more likely to have side effects from radiation therapy. About 208 men with early-stage prostate cancer will have their DNA tested for a marker linked to radiation sensitivity. Doctor…

This study checks if a special type of PET scan (PSMA PET) is more accurate than usual scans for seeing prostate cancer and how it responds to treatment. About 58 people with prostate cancer that is new or getting worse will take part. The goal is to see if this scan can better p…